Showing results (281-290 of 492) with videos related to
Sort By:
Pageof 50
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|October 27, 2020
Prenatal hepatitis B screening, and hepatitis B burden among children, in Ontario: a descriptive studyMia J Biondi, Alex Marchand-Austin, Kirby Cronin, et al.Haematologica|August 4, 2006
Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature reviewJane A Little, Vicki R McGowan, Gregory J Kato, et al.CMAJ Open|December 27, 2016
Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive studyAlison D Marshall, Sahar Saeed, Lisa Barrett, et al.Journal of Medical Virology|March 18, 2017
SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variantsMeleri Jones, Morven E Cunningham, Peter Wing, et al.AIDS (London, England)|January 29, 2014
Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South AfricaNatasha K Martin, Angela Devine, Jeffrey W Eaton, et al.Infectious Diseases and Therapy|May 7, 2017
Chronic Hepatitis C Treatment in Patients with Drug Injection History: Findings of the INTEGRATE Prospective, Observational StudyGeert Robaeys, Stefan Christensen, Damien Lucidarme, et al.Infectious Diseases and Therapy|April 8, 2026
Efficacy and Safety of Glecaprevir/Pibrentasvir in Participants with Chronic HCV Infection and Comorbidities or Multiple Concomitant Medications: An Integrated AnalysisCurtis Cooper, Shweta A Raina, Lisa Johnson, et al.Hepatology Communications|March 8, 2021
Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS StudyBertus Eksteen, Christopher L Bowlus, Aldo J Montano-Loza, et al.The New England Journal of Medicine|April 12, 2014
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirinJordan J Feld, Kris V Kowdley, Eoin Coakley, et al.Journal of Viral Hepatitis|February 6, 2023
The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysisIra M Jacobson, Stefan Bourgeois, Phillipe Mathurin, et al.Pageof 50